Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9592045 | 0.97 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL25435936 | 0.88 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL23581682 | 0.87 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4185937 | 0.84 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9068544 | 0.84 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4185933 | 0.84 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL6503886 | 0.82 | KDM4E (0.48) | CA1CA2CA7CA9TSHR | |
| SCHEMBL15178095 | 0.81 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL15178279 | 0.81 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL29607066 | 0.81 | CA1 (0.49) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4758608-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| US-7026440-B2 | Branched water soluble polymers containing atleast two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-04-11 | — | — | US | claimed |
| JP-2005508421-A | — | — | 2005-03-31 | — | — | JP | claimed |
| EP-1446438-A2 | BRANCHED POLYMERS AND THEIR CONJUGATES | Nektar Therapeutics Al, Corporation (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030143596-A1 | Branched water soluble polymers containing atleast two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent | SHEARWATER CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003040211-A2 | BRANCHED POLYMERS AND THEIR CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-20200048412-A1 | BRANCHED POLYMERS | NEKTAR THERAPEUTICS (US) | 2020-02-13 | — | — | US | disclosed |
| US-20160032049-A1 | BRANCHED POLYMERS | NEKTAR THERAPEUTICS | 2016-02-04 | — | — | US | disclosed |
| US-9187569-B2 | Branched polymers | NEKTAR THERAPEUTICS (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140329994-A1 | BRANCHED POLYMERS | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-8809453-B2 | Branched polymers | NEKTAR THERAPEUTICS (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130295639-A1 | Branched Polymers | NEKTAR THERAPEUTICS | 2013-11-07 | — | — | US | disclosed |
| US-8440816-B2 | Branched polymers | NEKTAR THERAPEUTICS (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110077362-A1 | Branched Polymers | NEKTAR THERAPEUTICS (US) | 2011-03-31 | — | — | US | disclosed |
| US-7872072-B2 | Branched water soluble polymers containing at least two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent; drugs/polymer conjugates/;bioavailability | NEKTAR THERAPEUTICS (US) | 2011-01-18 | — | — | US | disclosed |
| US-20060178475-A1 | Branched water soluble polymers containing at least two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent; drugs/polymer conjugates/;bioavailability | NEKTAR THERAPEUTICS | 2006-08-10 | — | — | US | disclosed |
| US-7026440-B2 | Branched water soluble polymers containing atleast two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1446438-A2 | BRANCHED POLYMERS AND THEIR CONJUGATES | Nektar Therapeutics Al, Corporation (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030143596-A1 | Branched water soluble polymers containing atleast two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent | SHEARWATER CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003040211-A2 | BRANCHED POLYMERS AND THEIR CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329994-A1 | BRANCHED POLYMERS | B2M, GNE, PAM | CA1 3735/4885CA2 4492/4885CA7 1373/4885 |
| US-20060178475-A1 | Branched water soluble polymers containing at least two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent; drugs/polymer conjugates/;bioavailability | OPRM1, B2M, AHR | CA1 3511/4885CA2 4155/4885CA7 1906/4885 |
| US-20200048412-A1 | BRANCHED POLYMERS | B2M, GNE, PAM | CA1 3735/4885CA2 4492/4885CA7 1373/4885 |
| US-20030143596-A1 | Branched water soluble polymers containing atleast two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent | ATL3, ASPH, UGT8 | CA1 2859/4885CA2 3768/4885CA7 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.